DEF 14A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities

Exchange Act of 1934 (Amendment No. )

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☒ Definitive Proxy Statement

☐ Definitive Additional Materials

☐ Soliciting Material Pursuant to §240.14a-12

EyePoint, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

☒ No fee required

☐ Fee paid previously with preliminary materials

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11



480 Pleasant Street, Suite C400 Watertown, MA 02472 United States
April 27, 2026 To Our Stockholders, 2025 was a year of exceptional execution for EyePoint as we advanced DURAVYU™ (vorolanib intravitreal insert), our potential first-in-class and best-in-class sustained delivery therapy, across clinical programs in the		We are well positioned as the leader in sustained ocular drug delivery as we endeavor to deliver on our mission to improve the lives of patients with serious retinal diseases.
two largest retinal disease markets, wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Throughout the past year, we made significant progress with DURAVYU, an investigational sustained release product candidate that consists of vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI), formulated in Durasert E™, our proprietary, next-generation bioerodible drug delivery technology. We enrolled over 900 patients across our two Phase 3 pivotal trials of DURAVYU in wet AMD – LUGANO and LUCIA – in what was one of the fastest enrolling Phase 3 programs in wet AMD to date. The identical non-inferiority trials with every six-month dosing follow a clear and recognized pathway for potential global regulatory and commercial success, which could enable DURAVYU to become a blockbuster franchise. In November 2025, we announced that the independent Data Safety Monitoring Committee (DSMC) for the wet AMD Phase 3 program completed its second scheduled review of masked data and recommended that both trials continue as planned with no modifications to the protocol. Additionally, the DSMC confirmed that the masked safety data continues to show no safety signals, which is consistent with previous clinical trials for DURAVYU. Looking ahead, we expect topline data for LUGANO in mid-2026 and for LUCIA shortly after. If we achieve clinical success we will prioritize our New Drug Application (NDA) filing, positioning DURAVYU to potentially be first to market. In February 2025, we announced positive six-month results for the Phase 2 VERONA clinical trial of DURAVYU for DME, which met primary and secondary endpoints and demonstrated early and sustained		FDA, we initiated the DME Phase 3 pivotal program and dosed the first patients in both clinical trials (COMO and CAPRI) in March 2026. COMO and CAPRI are identical trials that include every six-month redosing, an on-label control arm, and follow an established non-inferiority pathway for potential approval. Given the strong enrollment enthusiasm that we experienced in LUGANO and LUCIA for DURAVYU across the retina community, we expect to complete enrollment of our DME pivotal program in the third quarter of 2026 and to report topline data in the fourth quarter of 2027. We are excited to progress DURAVYU as the only sustained release TKI in development for this multi-billion-dollar market for which there is a significant need for new therapeutic options. The compelling efficacy data observed in the VERONA DME trial underscores DURAVYU’s potential as a mechanistically differentiated treatment for serious retinal diseases. Vorolanib, the active drug in DURAVYU, acts through intracellular inhibition of all vascular endothelial growth factor (VEGF) receptors, platelet-derived growth factor (PDGF) and pro-inflammatory interleukin 6 (IL-6)/JAK1 signaling. Preclinical data presented in October 2025 showed a greater than 50% reduction in IL-6 activity associated with DURAVYU via inhibition of JAK1 in an in vitro model. This finding reinforces the potential differentiating clinical value of DURAVYU for wet AMD and DME, where IL-6 mediated inflammation and VEGF-mediated vascular permeability are both key contributors to disease. From a safety perspective, DURAVYU has established a robust and favorable safety database from over 190 patients across multiple indications in four clinical trials with no safety signals. This exceptional safety profile, coupled with the strong efficacy data to date, gives us confidence in DURAVYU’s potential to transform how serious retinal diseases are treated.

      improvements in both vision and anatomy. Following this data and a positive End of Phase 2 meeting with the U.S. 
Beyond clinical development, we continue to scale operations at our state-of-the-art commercial manufacturing facility in Northbridge, Massachusetts. The cGMP facility was built to meet FDA and EMA standards, and will support the US commercial launch of DURAVYU upon potential regulatory approval. As we approach an anticipated NDA submission, we are actively preparing for pre-approval inspection and commercial build, underscoring our commitment to delivering DURAVYU to the retina community, if approved. We remain dedicated to investing in the people, processes, and technologies at the Northbridge facility.
Turning to our balance sheet, we are in a strong financial position. We ended 2025 with over $300 million in cash and investments and no debt, enabling us to fund operations into the fourth quarter of 2027, well beyond key 2026 milestones and NDA preparation for the Phase 3 wet AMD program while fully funding the Phase 3 pivotal DME program. 
EyePoint continues to be a story of a potential paradigm-altering treatment with DURAVYU, strong execution, and determined leadership in retinal disease. As a company, we are highly focused on reporting topline data for our Phase 3 wet AMD clinical trials beginning in mid-2026 and completing enrollment of our Phase 3 DME clinical trials. 
We are fortunate to have such a dedicated and talented team at EyePoint, who continue to drive our remarkable progress and are responsible for our company’s clinical, operational and financial success to date. In addition, we’d like to thank the patients and clinical investigators for their participation in our ongoing trials; without whom, advancing DURAVYU towards potential approval would not be possible. 

      With a world-class leadership team, robust Phase 2 efficacy and safety data, a clear and well-established regulatory approval pathway in wet AMD and DME, and a strong balance sheet, we are well positioned as the leader in sustained ocular drug delivery as we endeavor to deliver on our mission to improve the lives of patients with serious retinal diseases. 
On behalf of the entire EyePoint team and Board of Directors, we thank you, our committed stockholders, for your continued support as we continue to execute on our mission to improve the lives of patients with serious retinal diseases – because when it comes to matters of sight, innovation is our vision. 
Sincerely,
 
Jay S. Duker, M.D.
President & Chief Executive Officer
 
Göran Ando, M.D.
Chair of the Board

DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product candidate; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this proxy statement deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding our expectations regarding our clinical development and regulatory plans; our belief that DURAVYU is well-positioned to be first-in-class, best-in-class and the first-to-market among all investigational sustained release treatments for the two largest retinal disease markets, wet AMD and DME; our belief that DURAVYU is the only TKI in development for DME; our belief that DURAVYU is uniquely positioned to potentially address both VEGF-mediated vascular leakage and IL-6 mediated inflammatory drivers of DME as a sustained delivery therapy; our belief that DURAVYU’s potential real-world application in multiple retinal disease indications and established trial designs position DURAVYU for clinical and commercial success; our expectations regarding the timing of the availability and release of wet AMD and DME clinical data; our financial position and expected cash runway; our belief that DURAVYU has the potential to maintain a majority of patients with active disease with no supplemental anti-VEGF therapy for six months or longer; our beliefs regarding potential market opportunity for wet AMD and DME; our ability to continue to scale operations at our commercial manufacturing facility in Northbridge, Massachusetts; our expectations that our manufacturing facility will continue to meet FDA and EMA standards and support commercialization efforts of DURAVYU upon regulatory approval; and our expectations regarding the timing, and clinical and regulatory development, of DURAVYU and our other product candidates; and other statements regarding the Company’s future plans, obj

SEC Form DEF 14A filed by EyePoint Inc.